Effects of OK-432 on in vitro secondary responses of the non-adherent cells to IL-2 and OK-432 in cancer patients without tumor burden.
We examined the effect of OK-432 intracutaneous injection on the in vitro responses of non-adherent cells to IL-2 and OK-432, along with changes in lymphocyte subpopulations, in early cancer patients who underwent surgery. We found that 1) repeated injections of OK-432 resulted in an enhancement of LAK activity, the peak of which was seen between 7 and 10 days after the first administration, 2) this augmentation of LAK activity was not associated with changes in lymphocyte subpopulations CD8+ CD11- and CD8+ CD11+ phenotypes, and 3) the cytotoxic activity of lymphocytes stimulated in vitro with OK-432 did not show a definite change in specific pattern after in vitro OK-432 treatment. These findings indicate that repeated injections of OK-432 over a period of a week effectively enhanced LAK activity.
Fujieda
S
S
Department of Oto-Rhino-Laryngology, Fukui Medical School, Japan.
Saito
H
H
Isobe
Y
Y
Nakagawara
G
G
Nishi
O
O
Nagahara
K
K
Watanabe
Y
Y
Hoshino
T
T
D000328:Adult; D000368:Aged; D002448:Cell Adhesion / Q000187:drug effects; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects* / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D010641:Phenotype; D010844:Picibanil / Q000494:pharmacology*; D015375:Receptors, Interleukin-2 / Q000502:physiology
D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D010844:Picibanil